Kato, Ryoji
Hayashi, Hidetoshi http://orcid.org/0000-0001-8787-5587
Sakai, Kazuko
Suzuki, Shinichiro
Haratani, Koji
Takahama, Takayuki
Tanizaki, Junko
Nonagase, Yoshikane
Tanaka, Kaoru
Yoshida, Takeshi
Takeda, Masayuki
Yonesaka, Kimio
Kaneda, Hiroyasu
Nishio, Kazuto
Nakagawa, Kazuhiko
Funding for this research was provided by:
Nippon Boehringer Ingelheim
Article History
Received: 9 January 2021
Accepted: 25 May 2021
First Online: 11 June 2021
Declarations
:
: R. Kato has received lecture fees from Bristol-Myers Squibb Co. Ltd.; and honoraria from Eli Lilly Japan K.K. H. Hayashi has received honoraria from AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co. Ltd., Pfizer Japan Inc., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., Merck Biopharma Co. Ltd., and Taiho Pharmaceutical Co. Ltd.; and research funding from AbbVie Inc., AC MEDICAL Inc., Astellas Pharma Inc., AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., EPS Associates Co. Ltd., GlaxoSmithKline K.K., Japan Clinical Research Operations Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Merck Biopharma Co. Ltd., MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., PAREXEL International Corp., Pfizer Japan Inc., PPD-SNBL K.K., Quintiles Transnational Japan K.K., Taiho Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Yakult Honsha Co. Ltd. K. Sakai has received lecture fees from AstraZeneca K.K., Bio-Rad Laboratories, Inc., Chugai Pharmaceutical Co. Ltd., and Roche Diagnostics K.K., SRL, Inc. S. Suzuki has declared no conflicts of interest.K. Haratani has received honoraria from AstraZeneca K.K.; lecture fees from AS ONE Corporation, AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., MSD K.K., and Pfizer Japan Inc.; and research funding from AstraZeneca K.K. T. Takahama has received honoraria from AstraZeneca K.K., Roche Diagnostics K.K., and Nippon Boehringer Ingelheim Co. Ltd. J. Tanizaki has received honoraria from AstraZeneca K.K., Nippon Boehringer Ingelheim Co. Ltd, Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., MSD K.K., and Taiho Pharmaceutical Co. Ltd. Y. Nonagase has received honoraria from Taiho Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co. Ltd. K. Tanaka has received honoraria from AstraZeneca KK, Bristol-Myers Squibb, Eisai Co. Ltd., Merck Biopharma Co., and Ono Pharmaceutical Co. Ltd. T. Yoshida has received lecture fees from Bristol-Myers Squibb Co. Ltd., Daiichi Sankyo Co. Ltd., Hisamitsu Pharmaceutical Co. Inc., MundiPharma K.K., and Shionogi & Co. Ltd. M. Takeda has received honoraria from Chugai Pharmaceutical Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., and Ono Pharmaceutical Co. Ltd. K. Yonesaka has received research funding from Daiichi Sankyo Co. Ltd.; and honoraria from Nippon Boehringer Ingelheim Co. Ltd. H. Kaneda has received lecture fees from AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Nippon Kayaku Co. Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Pfizer Japan Inc., Taiho Pharmaceutical Co. Ltd.; and research funding from Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., MSD K.K., Novartis Pharma K.K., and Ono Pharmaceutical Co. Ltd. K. Nishio has received honoraria from AstraZeneca K.K., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., Guardant Health Inc., Kobayashi Pharmaceutical Co. Ltd., Life Technologies Japan Ltd., MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Pfizer Japan Inc., Roche Diagnostics K.K., Sanofi K.K., Solasia Pharma K.K., SymBio Pharmaceuticals Ltd., Takeda Pharmaceutical Co. Ltd., and Yakult Honsha Co. Ltd.; and research funding from Astellas Pharma Inc., Eli Lilly Japan K.K., Ignyta Inc., Korea Otsuka Co. Ltd., Life Technologies Japan Ltd., and Nippon Boehringer Ingelheim Co. Ltd. K. Nakagawa has received honoraria from Astellas Pharma Inc., AstraZeneca K.K., AYUMI Pharmaceutical Co., Bristol-Myers Squibb Co. Ltd., CareNet Inc., Chugai Pharmaceutical Co. Ltd., Clinical Trial Co. Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly Japan K.K., Hisamitsu Pharmaceutical Co. Inc., KYORIN Pharmaceutical Co. Ltd., Medical Review Co. Ltd., MEDICUS SHUPPAN Publishers Co. Ltd., MSD K.K., NANZANDO Co. Ltd., Nichi-Iko Pharmaceutical Co. Ltd., Nikkei Business Publications Inc., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Pfizer Japan Inc., Reno. Medical K.K., and SymBio Pharmaceuticals Ltd., Taiho Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Thermo Fisher Scientific K.K., YODOSHA Co. Ltd, and YOMIURI TELECASTING Co.; and research funding from A2 Healthcare Corp., AbbVie Inc., Astellas Pharma Inc., Bayer Yakuhin Ltd., Bristol-Myers Squibb Co. Ltd., Chugai Pharmaceutical Co. Ltd., CMIC Shift Zero K.K., Covance Inc., Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., EP-CRSU Co. Ltd., EPS Co., EPS international Co. Ltd., GlaxoSmithKline K.K., GRITSTONE ONCOLOGY Inc., ICON Japan K.K., inVentiv Health Japan, IQVIA Services JAPAN K.K., Kissei Pharmaceutical Co. Ltd., Kyowa Hakko Kirin Co. Ltd., Linical Co. Ltd., Merch Serono Co. Ltd., MSD K.K., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., PAREXEL International Corp., Pfizer Japan Inc., Quintiles Inc., SymBio Pharmaceuticals Ltd., Taiho Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Yakult Honsha Co. Ltd.; and consulting or advisory fees from Astellas Pharma Inc., Eli Lilly Japan K.K., Ono Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co. Ltd.